Atypical Antipsychotic Quetiapine in the Management of Severe Refractory Functional Gastrointestinal Disorders
- 259 Downloads
Management of severe refractory functional gastrointestinal disorders (FGIDs) is difficult. Quetiapine, an atypical antipsychotic, may benefit patients by mitigating associated anxiety and sleep disturbances, augmenting the effect of antidepressants, and providing an independent analgesic effect. Outpatient records from a university-based FGID clinic were reviewed, and 21 patients with refractory symptoms who received quetiapine were identified and interviewed. Outcomes included global relief of symptoms, treatment efficacy questionnaire, and change in gastrointestinal (GI) and psychological symptoms. Eleven of 21 patients continued therapy at the time of interview. Six of 11 demonstrated global relief of symptoms, and 9 were satisfied with treatment. The remaining 10 of 21 discontinued therapy because of somnolence and lack of GI benefits. Quetiapine in low doses appeared beneficial in more than half of the adults with severe FGIDs who stayed on treatment. This response in otherwise refractory patients suggests quetiapine might augment the effectiveness of antidepressants in severe FGIDs.
KeywordsIrritable bowel syndrome Functional gastrointestinal disorders Treatment Psychotropic agents Antidepressants Quetiapine Atypical antipsychotics
Supported by the Gastrointestinal Biopsycho-social Research Center at UNC, NIH R24Dk067674.
- 1.Creed F, Levy R, Bradley L, et al. Psychosocial aspects of functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:295–368.Google Scholar
- 2.Thiwan SM, Drossman DA. Treatment of functional GI disorders with psychotropic medicines: a review of evidence with a practical approach. Gastroenterol Hepatol. 2006;2:678–688.Google Scholar
- 8.Creswell JW. Research Design. Qualitative, Quantitative and Mixed Methods Approaches. 2nd ed. California: Sage Publications; 2003.Google Scholar
- 10.Drossman DA. The functional gastrointestinal disorders and the Rome III process. In: Drossman DA, Corazziari E, Delvaux M, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:1–29.Google Scholar
- 11.Longstreth G, Thompson W, Chey W, Houghton L, et al. Functional bowel disorders. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al., eds. Rome III: The Functional Gastrointestinal Disorders. McLean, VA: Degnon Associates Inc.; 2006:487–555.Google Scholar
- 23.McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24:487–494. doi: 10.1002/da.20275.PubMedCrossRefGoogle Scholar
- 24.Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999;35(3):193–210.Google Scholar
- 28.Cohrs S, Rodenbeck A, Guan Z, et al. Sleep promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004;174:421–429.Google Scholar
- 30.Shemo M, Shemo JPD, Anderson M. Beneficial effects of quetiapine treatment in patients with fibromyalgia. J Neuropsychiatry Clin Neurosci. 2003;15:282.Google Scholar
- 34.Hellewell JSE, Hands DC, McKellar J. Seroquel: an effective atypical antipsychotic with no greater EP’S than placebo across the full dose range. Schizophr Res. 1998;29:154–155.Google Scholar
- 36.Drossman DA, Chang L. Psychosocial factors in the care of patients with GI disorders. In: Yamada T, ed. Textbook of Gastroenterology, Chapter 29. Philadelphia: Lippincott; 2003:636–654.Google Scholar